Connect Biopharma Holdings Limited Forecasted to Earn FY2022 Earnings of ($1.10) Per Share (NASDAQ:CNTB)

Connect Biopharma Holdings Limited (NASDAQ:CNTBGet Rating) – Equities researchers at Jefferies Financial Group raised their FY2022 EPS estimates for Connect Biopharma in a research note issued to investors on Tuesday, September 13th. Jefferies Financial Group analyst K. Shi now expects that the company will earn ($1.10) per share for the year, up from their previous estimate of ($2.12). The consensus estimate for Connect Biopharma’s current full-year earnings is ($2.17) per share. Jefferies Financial Group also issued estimates for Connect Biopharma’s FY2023 earnings at ($2.19) EPS, FY2024 earnings at ($1.95) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.70) EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Connect Biopharma in a research report on Thursday, June 2nd.

Connect Biopharma Stock Down 1.4 %

NASDAQ:CNTB opened at $1.44 on Friday. The firm’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.69. Connect Biopharma has a one year low of $0.56 and a one year high of $25.25.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CNTB. Ensign Peak Advisors Inc acquired a new position in shares of Connect Biopharma in the fourth quarter worth about $131,000. Deep Track Capital LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $3,332,000. Altium Capital Management LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $901,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $6,438,000. Finally, DLD Asset Management LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $627,000. Institutional investors and hedge funds own 27.19% of the company’s stock.

Connect Biopharma Company Profile

(Get Rating)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

Featured Articles

Earnings History and Estimates for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.